ProKidney (PROK) News
NASDAQ: PROKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.04-0.02 (-1.89%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PROK news summary
We found 6 recent headlines mentioning ProKidney (PROK): 2 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, PROK is down 1.89% at $1.04. The most recent story, "ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial Advances", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ProKidney headlines
- ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial Advances(RTTNews) - ProKidney Corp. (PROK) on Wednesday announced the promotion of Farah Ali as Chief Medical Officer (CMO) to lead its clinical program as the company advances the pivotal Phase 3 PROACT 1…NasdaqABBV, AMGN, IMVT, PROK
- ProKidney Names Farah Ali, M.D., M.S., Chief Medical OfficerDr. Ali expands her role at ProKidney, bringing experience as a board-certified pediatric nephrologist and clinical development leader as the Company prepares for anticipated clinical milestones and…GlobeNewswire
- ProKidney Reports Third Quarter 2026 Financial Results and Business HighlightsWINSTON-SALEM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney…GlobeNewswire
- ProKidney Corp. Reports $141.9 million in Cash and Outlines Phase 3 PROACT 1 MilestonesProKidney Corp. reported that its cash and cash equivalents and marketable securities as of September 30, 2026 was $141.9 million.Nasdaq
- ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate UpdateWINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney…GlobeNewswire
- ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney…GlobeNewswire